Are real time data and lane risk assessments worth it?

Pharma supply chain leaders are under pressure to do more with less — faster product releases, fewer excursions, better compliance, and greater sustainability. But are real-time data and lane risk assessment silver bullets or just buzzwords?

Agenda

 

  • Opening Keynote

  • S+O Data Framework: Combining Simulation and Operational data

  • From Data to Action: The intervention gap

  • AI in Pharma: Where it helps, where it doesn’t

  • Q&A and Closing Remarks

LogiPharma 2024 Nico Ros Masterclass 43